 |
市場調查報告書
商品編碼
1791926
乾癬市場:KOL的洞察KOL Insight - Psoriasis |
||||||
本報告探討了銀屑病治療領域的發展趨勢，重點關注Skylizy、Tremfya和Bimzelx等領先生物製劑的臨床和市場影響，預計這些藥物將在未來五年內主導銀屑病治療領域。報告也分析了伊曲庫寧對口服治療領域的影響，尤其是其對奧特茲拉（Otezla）市場定位的影響，並評估了阿達木單抗和優特克單抗等生物相似藥在關節炎和斑塊狀乾癬一線治療中日益重要的作用。報告深入探討了不斷變化的處方模式、早期生物製劑應用的推動因素，以及這些發展對未來治療策略和市場動態的影響。
關鍵問題
- 目前核准的乾癬藥物是如何被臨床醫師使用和認知的？
- 已上市藥物及在研藥物在療效、安全性和給藥有何比較？
- 哪些藥物類別預計將對未來乾癬處方趨勢產生最大影響？
- 生物相似藥將如何影響乾癬治療模式和病患管理？
- 哪些在研產品最有可能改變目前的市場格局？
- 哪些正在進行或即將進行的臨床試驗有可能顯著影響乾癬治療策略？
- 治療格局將如何演變？患者群體和治療線將如何演變？
- 新型口服藥物在乾癬管理中的預期作用和表現如何？
- 乾癬市場中關鍵意見領袖 (KOL) 的期望和未滿足的需求是什麼？
- 新型療法的推出將如何影響目前的治療方案和關鍵參與者？
領導品牌
|
|
|
部分參加專家名單
- 加州大學洛杉磯分校大衛‧格芬醫學院皮膚科臨床助理教授。
- 耶魯大學醫學院皮膚病學副教授兼乾癬治療計畫主任。
- 加州大學洛杉磯分校皮膚病學首席教授。
- 法國巴黎聖路易醫院皮膚科教授。
- 西班牙巴塞隆納聖克魯斯-聖保羅醫院皮膚科主任。
- 瑞士洛桑大學醫院皮膚科教授。
研究方法：
"治療趨勢" 報告透過對全球領先的關鍵意見領袖 (KOL) 進行深入訪談，探討關鍵疾病領域的當前和未來治療前景。 KOL 的遴選是基於嚴格的標準，包括全球知名度、臨床專業知識以及在其治療領域的影響力。每次訪談均配有精心編寫的討論指南。這些指南由我們與 KOL 合作制定，並由行業專家進行同行評審，以確保問題全面且與當前市場動態相關。每份報告發布後，我們都會持續進行12個月的市場監測，以便及時更新 KOL 對重要新聞事件、市場變化和市場發展的最新動態。
報告特色
FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供深入可行的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助客戶掌握新興趨勢，有效應對複雜課題。憑藉廣泛的研究以及來自頂尖專家和關鍵意見領袖 (KOL) 的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家訪談和數據，以及持續的市場監測，確保您能夠全面了解市場動態。我們的報告涵蓋 40 多個活躍的疾病領域，包括 KOL 洞察和定量醫生調查在內的醫生情報，以及行業專家對醫療事務、數位健康、銷售和行銷、市場准入等領域問題的看法，幫助您做出更明智的數據驅動決策，並在快速變化的行業中保持競爭力。
This report examines the evolving landscape of psoriasis treatment, with a focus on the clinical and market impact of leading biologics-including Skyrizi, Tremfya, and Bimzelx-which are projected to dominate the therapeutic pathway over the next five years. It analyses the anticipated influence of icotrokinra on the oral therapy segment, particularly its effect on Otezla's positioning, and evaluates the expanding role of biosimilars such as adalimumab and ustekinumab in first-line management for joint and plaque psoriasis. Gain insights into shifting prescribing patterns, the drivers behind earlier biologic use, and the implications of these developments for future treatment strategies and market dynamics.
Key Questions Answered:
- How are currently approved therapies for psoriasis used and perceived by clinicians?
- How do marketed therapies compare with pipeline treatments in efficacy, safety, and administration?
- Which drug classes are expected to most influence future prescribing trends in psoriasis?
- What impact will biosimilars have on the psoriasis treatment paradigm and patient management?
- Which pipeline products show the most promise for changing the current market landscape?
- Which ongoing or upcoming clinical trials could significantly affect psoriasis treatment strategies?
- How will the treatment landscape evolve for different patient segments and lines of therapy?
- What is the expected role and performance of new oral therapies in psoriasis management?
- What are KOLs' expectations and unmet needs in the psoriasis market?
- How will the introduction of new therapies affect current treatment algorithms and key players?
Key Brands:
|
|
|
Partial List of Participating Experts:
- Clinical Assistant Professor of Medicine, Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
- Assistant Professor of Dermatology; Director, Psoriasis Treatment Program, Department of Dermatology, Yale School of Medicine, New Haven, CT.
- Professor and Chief of Dermatology, University of California Los Angeles, Los Angeles, CA.
- Professor of Dermatology at Hopital Saint-Louis, Paris, France.
- Director of the Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- Professor of Dermatology, Lausanne University Hospital, Lausanne, Switzerland.
Methodology:
Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
